Welcome to the Bioclinica Portal Launch Page. Please select your appropriate portal for access.
- Bioclinica SMART Portal – The SMART Portal provides insights for self-service capabilities for clinical sites and study teams to view imaging and enrollment information, manage queries, download submitted images, and more.
- SMART Reports – SMART Reports provides Sponsor study teams and CRO staff with data and analytics related to medical imaging and trial performance. Access to SMART Reports can be requested through your Bioclinica project manager.
- BioPACS/BioREAD Reports Portal – This reporting system provides information for a selection of oncology and gastroenterology studies managed at Bioclinica.
- Clinical Adjudication System (TAP) – This flexible system provides workflows needed for the clinical adjudication process, along with complete transparency for sponsors.
LEARN MORE OR SPEAK WITH OUR EXPERTS
CONTACT USLeader in Clinical Trial
Management Solutions
Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.
Quick Links:
Language:
With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo